JP2022511588A5 - - Google Patents

Info

Publication number
JP2022511588A5
JP2022511588A5 JP2021504441A JP2021504441A JP2022511588A5 JP 2022511588 A5 JP2022511588 A5 JP 2022511588A5 JP 2021504441 A JP2021504441 A JP 2021504441A JP 2021504441 A JP2021504441 A JP 2021504441A JP 2022511588 A5 JP2022511588 A5 JP 2022511588A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
approximately
diuretic
Prior art date
Application number
JP2021504441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511588A (ja
JPWO2020021341A5 (https=
JP7474738B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000923 external-priority patent/WO2020021341A1/en
Publication of JP2022511588A publication Critical patent/JP2022511588A/ja
Publication of JPWO2020021341A5 publication Critical patent/JPWO2020021341A5/ja
Publication of JP2022511588A5 publication Critical patent/JP2022511588A5/ja
Priority to JP2024062293A priority Critical patent/JP2024099574A/ja
Application granted granted Critical
Publication of JP7474738B2 publication Critical patent/JP7474738B2/ja
Priority to JP2025175743A priority patent/JP2026031933A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021504441A 2018-07-26 2019-07-26 高血圧症の処置のための組成物 Active JP7474738B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024062293A JP2024099574A (ja) 2018-07-26 2024-04-08 高血圧症の処置のための組成物
JP2025175743A JP2026031933A (ja) 2018-07-26 2025-10-17 高血圧症の処置のための組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862703802P 2018-07-26 2018-07-26
US62/703,802 2018-07-26
PCT/IB2019/000923 WO2020021341A1 (en) 2018-07-26 2019-07-26 Compositions for the treatment of hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024062293A Division JP2024099574A (ja) 2018-07-26 2024-04-08 高血圧症の処置のための組成物

Publications (4)

Publication Number Publication Date
JP2022511588A JP2022511588A (ja) 2022-02-01
JPWO2020021341A5 JPWO2020021341A5 (https=) 2022-08-02
JP2022511588A5 true JP2022511588A5 (https=) 2022-08-02
JP7474738B2 JP7474738B2 (ja) 2024-04-25

Family

ID=69179579

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021504441A Active JP7474738B2 (ja) 2018-07-26 2019-07-26 高血圧症の処置のための組成物
JP2024062293A Pending JP2024099574A (ja) 2018-07-26 2024-04-08 高血圧症の処置のための組成物
JP2025175743A Pending JP2026031933A (ja) 2018-07-26 2025-10-17 高血圧症の処置のための組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024062293A Pending JP2024099574A (ja) 2018-07-26 2024-04-08 高血圧症の処置のための組成物
JP2025175743A Pending JP2026031933A (ja) 2018-07-26 2025-10-17 高血圧症の処置のための組成物

Country Status (11)

Country Link
US (2) US20200030296A1 (https=)
EP (1) EP3826633A4 (https=)
JP (3) JP7474738B2 (https=)
KR (1) KR20210038931A (https=)
CN (1) CN112770746A (https=)
AU (2) AU2019309329B2 (https=)
BR (1) BR112021001374A2 (https=)
CA (1) CA3107616A1 (https=)
MX (2) MX2021001043A (https=)
WO (1) WO2020021341A1 (https=)
ZA (1) ZA202006591B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240096848A (ko) 2017-01-25 2024-06-26 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물
US12521380B2 (en) * 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
WO2025226012A1 (ko) * 2024-04-23 2025-10-30 신풍제약주식회사 칸데사르탄, 암로디핀 및 인다파미드를 포함하는 고혈압 예방 또는 치료용 약제학적 복합제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20070293552A1 (en) * 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
EP2545920A1 (en) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
KR20090057538A (ko) * 2007-12-03 2009-06-08 박사룡 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN101618215A (zh) * 2009-08-16 2010-01-06 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
EP2575808A1 (en) * 2010-05-28 2013-04-10 Mahmut Bilgic Combination of antihypertensive agents
CZ2015687A3 (cs) * 2015-10-02 2017-04-12 Zentiva, K.S. Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
US10369156B2 (en) * 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension

Similar Documents

Publication Publication Date Title
RU2019126749A (ru) Композиции для лечения гипертензии
JP2020506180A5 (https=)
JP2022511588A5 (https=)
RU2004137105A (ru) Комбинация органических соединений
AU753486B2 (en) Method of treatment and pharmaceutical composition
RU2014111474A (ru) Способы лечения сердечно-сосудистых нарушений
NZ596395A (en) Stable solid benzimidazole derivative preparation having optimized dissolution property
EA200501075A1 (ru) Лекарственное средство для профилактики и лечения артериосклероза и гипертензии
AR039329A1 (es) Derivados de triazol, antagonistas de receptor de taquicinina
JP2020536919A5 (https=)
FI3952880T3 (fi) 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dioni käytettäväksi non-hodgkinin lymfooman hoidossa
EA200800710A1 (ru) Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора
RU2006127572A (ru) Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
PE20110844A1 (es) Composicion farmaceutica solida
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
WO2017054787A1 (en) Pharmaceutical composition comprising the combination of candesartan, amlodipine and hydrochlorothiazide
JPWO2020021341A5 (https=)
GEP20115309B (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihy-droxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-arboxylic acid ethylamide and formulations comprising these forms
HRP20171209T1 (hr) Farmaceutski pripravak za liječenje upalnih bolesti posredovanih putem mcp-1
JP6532984B2 (ja) 高血圧症の予防又は治療のための併用医薬
RU2021103512A (ru) Композиции для лечения гипертензии
BR0009582A (pt) Composto, composição farmacêutica, e, processopara o tratamento de uma condição de doençaselecionada de artrite reumatóide, doença dealzheimer, câncer, esquizofrenia, edema, rinitealérgica, inflamação, dor, hipermobilidadegastrointestinal , asma gástrica, refluxogastroesfageal, ansiedade, emese, doença dehuntington, psicoses incluindo depressão,hipertensão, enxaqueca e urticária
RU2023129881A (ru) Композиции для лечения гипертензии
RU2001132073A (ru) Фармацевтическая композиция для предотвращения, лечения или ингибирования развития простой ретинопатии и препролиферирующей ретинопатии